Join to View Full Profile
1910 Royalty DrPomona, CA 91767
Phone+1 909-630-7342
Fax+1 909-630-7380
Dr. Ebrahimi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
Baylor College of MedicineResidency, Internal Medicine, 1997 - 2000- Baylor College of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 2002 - 2026
TX State Medical License 1998 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Publications & Presentations
PubMed
- 6 citationsPharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis.Behnam Ebrahimi, Suryavathi Viswanadhapalli, Uday P Pratap, Gopalam Rahul, Xue Yang
NPJ Precision Oncology. 2024-05-24 - 3 citationsTargeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34.Kristin A Altwegg, Uday P Pratap, Zexuan Liu, Junhao Liu, John R Sanchez
Breast Cancer Research and Treatment. 2023-07-01 - 7 citationsA First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.Kristin A Altwegg, Suryavathi Viswanadhapalli, Monica Mann, Dimple Chakravarty, Samaya Krishnan
Cancer Research. 2022-10-17
Press Mentions
CliniCians Southern CaliforniaSeptember 28th, 1999
Grant Support
- Identifying Mechanisms of Resistance to SLC6AB Inhibition in CRC Liver MetastasisROCKEFELLER UNIVERSITY2025–2028
- Targeting chemotherapy resistant high grade serous ovarian cancerUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2023–2025
- Targeting chemotherapy resistant high grade serous ovarian cancerUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2023–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
